| Institution: | 1. Department of Cardiac and Thoracic Vascular Surgery, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck Campus, Lübeck, Germany;2. German Center for Cardiovascular Research (DZHK), Partner Site Lübeck, Lübeck, Germany;3. Department of Cardiac Surgery, University of Bonn, Bonn, Germany;4. Department of Cardiology, University Hospital Schleswig-Holstein, Lübeck Campus, Lübeck, Germany;5. Sana Cardiac Surgery Stuttgart, Stuttgart, Germany;6. Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria;7. Department of Thoracic and Cardiovascular Surgery, University Hospital Frankfurt, Frankfurt, Germany;8. Department of Cardiovascular Surgery, University Hospital Würzburg, Würzburg, Germany;9. Department of Cardiac and Vascular Surgery, Robert-Bosch-Hospital, Stuttgart, Germany;10. Centre of Cardiovascular Surgery and Transplantation, Brno, Czech Republic;11. Department of Congenital Heart Disease and Paediatric Cardiology, German Heart Center, Berlin, Germany;12. Department of Cardiovascular Surgery, German Heart Center, Munich, Germany;13. Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany |
| Abstract: | BackgroundTreatment of aortic-valve disease in young patients still poses challenges. The Ross procedure offers several potential advantages that may translate to improved long-term outcomes.ObjectivesThis study reports long-term outcomes after the Ross procedure.MethodsAdult patients who were included in the Ross Registry between 1988 and 2018 were analyzed. Endpoints were overall survival, reintervention, and major adverse events at maximum follow-up. Multivariable regression analyses were performed to identify risk factors for survival and the need of Ross-related reintervention.ResultsThere were 2,444 adult patients with a mean age of 44.1 ± 11.7 years identified. Early mortality was 1.0%. Estimated survival after 25 years was 75.8% and did not statistically differ from the general population (p = 0.189). The risk for autograft reintervention was 0.69% per patient-year and 0.62% per patient-year for right-ventricular outflow tract (RVOT) reintervention. Larger aortic annulus diameter (hazard ratio HR]: 1.12/mm; 95% confidence interval CI]: 1.05 to 1.19/mm; p < 0.001) and pre-operative presence of pure aortic insufficiency (HR: 1.74; 95% CI: 1.13 to 2.68; p = 0.01) were independent predictors for autograft reintervention, whereas the use of a biological valve (HR: 8.09; 95% CI: 5.01 to 13.08; p < 0.001) and patient age (HR: 0.97 per year; 95% CI: 0.96 to 0.99; p = 0.001) were independent predictors for RVOT reintervention. Major bleeding, valve thrombosis, permanent stroke, and endocarditis occurred with an incidence of 0.15% per patient-year, 0.07% per patient-year, 0.13%, and 0.36% per patient-year, respectively.ConclusionsThe Ross procedure provides excellent survival over a follow-up period of up to 25 years. The rates of reintervention, anticoagulation-related morbidity, and endocarditis were very low. This procedure should therefore be considered as a very suitable treatment option in young patients suffering from aortic-valve disease. (Long-Term Follow-up After the Autograft Aortic Valve Procedure Ross Operation]; NCT00708409) |
